See more : Grand Fortune Securities Co.,Ltd (6026.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Helius Medical Technologies, Inc. (HSDT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helius Medical Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- ZTEST Electronics Inc. (ZTE.CN) Income Statement Analysis – Financial Results
- Vestas Wind Systems A/S (VWSB.DE) Income Statement Analysis – Financial Results
- Telecom Argentina S.A. (TEO) Income Statement Analysis – Financial Results
- HTM International Holding Ltd. (4924.TWO) Income Statement Analysis – Financial Results
- Oliver’s Real Food Limited (OLI.AX) Income Statement Analysis – Financial Results
Helius Medical Technologies, Inc. (HSDT)
About Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 644.00K | 787.00K | 522.00K | 661.00K | 1.50M | 478.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 583.00K | 463.00K | 298.00K | 388.00K | 846.00K | 0.00 | 0.00 | 0.00 | 171.78K | 0.00 | 0.00 |
| Gross Profit | 61.00K | 324.00K | 224.00K | 273.00K | 650.00K | 478.00K | 0.00 | 0.00 | -171.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 9.47% | 41.17% | 42.91% | 41.30% | 43.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.94M | 4.26M | 5.99M | 4.58M | 8.06M | 9.94M | 14.39M | 4.72M | 3.83M | 171.78K | 4.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.21M | 8.47M | 5.65M | 4.26M | 895.50K | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 774.40K | 0.00 | 0.00 |
| SG&A | 9.27M | 10.64M | 12.18M | 9.71M | 16.52M | 17.21M | 8.47M | 5.65M | 5.04M | 895.50K | 4.27M |
| Other Expenses | 276.00K | 181.00K | 200.00K | 363.00K | 64.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.49M | 15.08M | 18.37M | 14.66M | 24.65M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Cost & Expenses | 13.07M | 15.55M | 18.66M | 15.05M | 25.49M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Interest Income | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.00K | 20.07K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 1.95M | 5.17M | 1.67M | 176.49K | 0.00 | 0.00 |
| Depreciation & Amortization | 162.00K | 306.00K | 374.00K | 482.00K | 191.00K | 59.00K | 17.00K | 1.78M | 20.07K | 0.00 | 0.00 |
| EBITDA | -12.11M | -14.50M | -17.82M | -13.90M | -23.93M | -26.62M | -17.67M | -8.60M | -6.83M | -1.07M | -8.52M |
| EBITDA Ratio | -1,879.97% | -2,044.73% | -3,439.08% | -2,132.68% | -2,535.09% | -5,147.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.43M | -14.76M | -18.14M | -14.39M | -24.00M | -26.68M | -22.85M | -10.37M | -8.86M | -1.07M | -8.52M |
| Operating Income Ratio | -1,929.81% | -1,875.35% | -3,475.48% | -2,176.40% | -1,604.01% | -5,580.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.58M | 687.00K | 10.00K | 72.00K | 14.22M | -1.95M | -5.17M | -1.67M | 1.98M | 0.00 | 0.00 |
| Income Before Tax | -8.85M | -14.07M | -18.13M | -14.13M | -9.78M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | -8.52M |
| Income Before Tax Ratio | -1,374.22% | -1,788.06% | -3,473.56% | -2,137.67% | -653.81% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.51M | -10.00K | -193.00K | -14.12M | 3.96M | 10.34M | 1.67M | -146.62K | 0.00 | -8.52M |
| Net Income | -8.85M | -12.56M | -18.12M | -13.94M | 4.34M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | 0.00 |
| Net Income Ratio | -1,374.22% | -1,595.68% | -3,471.65% | -2,108.47% | 290.04% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| EPS Diluted | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to...
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to...
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle --
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August 14, 2024, its independent directors approved equity awards under Helius' 2021...
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - CFO Conference Call Participants Anthony Vendetti - Maxim...
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended...
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will...
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke -- -- In Canada, an additional study on the use...
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate...
Source: https://incomestatements.info
Category: Stock Reports